Ken Griffin Cullinan Oncology, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 40,600 shares of CGEM stock, worth $470,960. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,600

Previous 34,100 19.06%

Holding current value

$470,960

Previous $594,000 14.31%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$16.03 - $20.86 $194,251 - $252,781	12,118 Added 0.62%	1,955,257 $32.7 Million
Q2 2024 Aug 14, 2024	BUY	$15.63 - $29.35 $13 Million - $24.5 Million	833,968 Added 75.19%	1,943,139 $33.9 Million
Q1 2024 May 15, 2024	SELL	$10.17 - $19.02 $241,212 - $451,116	-23,718 Reduced 2.09%	1,109,171 $18.9 Million
Q4 2023 Feb 14, 2024	BUY	$7.89 - $10.23 $535,265 - $694,013	67,841 Added 6.37%	1,132,889 $11.5 Million
Q3 2023 Nov 14, 2023	BUY	$9.05 - $11.72 $78,707 - $101,928	8,697 Added 0.82%	1,065,048 $9.64 Million
Q2 2023 Aug 14, 2023	BUY	$8.8 - $13.4 $3.81 Million - $5.81 Million	433,283 Added 69.54%	1,056,351 $11.4 Million
Q1 2023 May 15, 2023	BUY	$10.2 - $11.91 $3.86 Million - $4.5 Million	377,958 Added 154.2%	623,068 $6.37 Million
Q4 2022 Feb 14, 2023	BUY	$9.72 - $13.62 $92,408 - $129,485	9,507 Added 4.04%	245,110 $2.59 Million
Q3 2022 Nov 14, 2022	SELL	$11.82 - $15.42 $1.58 Million - $2.06 Million	-133,867 Reduced 36.23%	235,603 $3.02 Million

Others Institutions Holding CGEM

# of Institutions

146

Shares Held

67.6M

Call Options Held

612K

Put Options Held

118K

View Full List

About Cullinan Oncology, Inc.

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $529M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

More about CGEM

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account